메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

HCSA Community Services and Tan Tock Seng Hospital Sign M…

SINGAPORE, July 28, 2025 -- In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C. This marks a significant step towards the Educate, Test, Treat! (ETT) initiative, launched in 2022 with the funding support of Gilead Sciences. Witnessed by Mdm Rahayu Mahza
- 김갑성 기자
- 2025-07-28 16:11
Successful Completion of First CRS with HIPEC on a 60-year-old W…

KOLKATA, India, July 28, 2025 -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated with Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Manipal Hospital Dhakuria, under the expertise of Dr. Ashutosh Daga, Medical Oncologist, and Dr. Sagnik Ray, Surgical Oncologist. The 12-hour long procedure adds a milestone in cancer care treatment. The sexagenarian was initially taken to another hospital where she was misdiagnosed as a case of chronic liver failure with ascites
- 김갑성 기자
- 2025-07-28 15:20
Plasmatreat Introduces HydroPlasma®: 高性能表面洗浄における持続…

ドイツ・シュタインハーゲン, 2025年7月26日 -- 大気圧プラズマ技術の世界的リーダーであるPlasmatreat GmbHは、ガラスや金属表面を超高精度で洗浄する革新的かつ環境に優しいソリューションHydroPlasma®を発表しました。Openair-Plasma®の実証された効果とイオン化水の反応力を組み合わせた HydroPlasma®は、指紋、油分、塩分、グリースなどの頑固な有機・無機汚染物を化学薬品を使わずに除去する新たな基準を打ち立てます。ハイテク産業とプロセスにおける洗浄の革命自動車、電子機器、航空宇宙、医療機器製造などの分野では、微細な汚染物でさえ、接着、コーティング、印刷、シーリングといった重要な工程での密着性を損なう可能性があります。従来の洗浄方法は溶剤や湿式化学処理に頼ることが多いですが、HydroPlasma® は圧縮空気、電気、水のみを使用し、化学薬品を使わない持続可能な代替手段を提供します。この先進技術は、洗浄効率を高めるだけでなく、環境に配慮した生産活動も支援します。 HydroPlasma®の仕組み：科学と持続可能性の融合 HydroPlasma®の特許取得済みプロセ
- 김갑성 기자
- 2025-07-28 15:03
플라스마트리트, 하이드로플라스마® 출시… 고성능 표면 세척 위한 지속 가능한 신기술

슈타인하겐, 독일, 2025년 7월 26일 -- 대기 플라스마 기술 분야의 글로벌 선도 기업 플라스마트리트 유한책임회사(Plasmatreat GmbH)가 유리 및 금속 표면의 초정밀 세척을 위한 혁신적이고 친환경적인 솔루션 하이드로플라스마(HydroPlasma®)를 출시했다. 오픈에어 플라스마(Openair-Plasma®)의 검증된 효능에 이온화된 물의 반응성을 결합한 하이드로플라스마®는 지문, 기름, 염분, 그리스 등 제거가 까다로운 유기 및 무기 오염 물질을 화학 약품 없이 제거함으로써 세정 기술의 새로운 기준을 제시하고 있다. 하이테크 산업 및 공정의 세정 혁신 자동차, 전자, 항공우주, 의료 제조 등 다양한 산업 분야에서는 미세한 오염 물질조차도 접착, 코팅, 인쇄, 밀봉 등 주요 공정에서 접착력에 영향을 줄 수 있다. 기존 세정 방식은 일반적으로 용제나 습식 화학 처리에 의존해 왔으나 하이드로플라스마®는 압축 공기, 전기, 물만을 사용해 화학 물질 없이 지속 가능한 대안을 제공한다. 이 첨단 기술은 세정 효율을 높이는 동시에 친환경적인
- 김갑성 기자
- 2025-07-28 15:03
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosim…

[ 메디채널 김갑성 기자 ] CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharmaceutical DAEJEON, South Korea, July 28, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI® (code name: ALT-L9), a bi
- 김갑성 기자
- 2025-07-28 14:00
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALA…

KUALA LUMPUR, Malaysia, July 28, 2025 -- The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, officiated the event, unveiling the campaign's logo and tagline, "Healing Meets Hospitality." MYMT 2026 aims to position Malaysia as a premier medical tourism destination by showcasing its advanced healthcare services and hospitality. The campaign also seeks to attract international heal
- 김갑성 기자
- 2025-07-28 12:17
NMPA Accepts sNDA for Ivonescimab in Combination with Chem…

HONG KONG, July 28, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metasta
- 김갑성 기자
- 2025-07-28 12:14
Antengene Announces Poster Presentation of ATG-022 (Clau…

SHANGHAI and HONG KONG, July 28, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17t
- 김갑성 기자
- 2025-07-28 10:40
Antengene Announces XPOVIO® Approved in China for the Se…

This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China. XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List. Results from the BENCH
- 김갑성 기자
- 2025-07-28 10:35
Ascletis Announces First Participants with Obesity or Overweig…

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1 receptor agonist ASC30. - Ultra-long-acting SQ depot formulation of small molecule ASC30 demonstrated a 36-day half-life in participants with obesity in the Phase Ib study, supporting once monthly administration. - Phase Ib study also demonstrated that compared to the trough concentration of ASC30 at Day 29, the ultra-long-acting SQ d
- 김갑성 기자
- 2025-07-28 08:15

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분